



ERIC HOLCOMB, GOVERNOR
STATE OF INDIANA

Office of Medicaid Policy and Planning
MS 07, 402 W. WASHINGTON STREET, ROOM W382
INDIANAPOLIS, IN 46204-2739

MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee

August 5, 2022

9 A.M. EDT

Virtual Meeting - Microsoft Teams Link Provided Below

1. Call to Order-Chair
2. Opening Comments-OMPP
3. Approval of Memoranda, Meeting of May 6, 2022
4. Preferred Drug List: Therapeutic Class Re-Review
 - a) Respiratory
 - i. Antihistamine-Decongestant Combinations/2nd Generation Antihistamines
 - ii. Antiviral Monoclonal Antibodies
 - iii. Beta Adrenergics and Corticosteroids
 - iv. Beta Agonists
 - v. Bronchodilator Agents - Beta Adrenergic and Anticholinergic Combinations
 - vi. Leukotriene Receptor Antagonists
 - vii. Monoclonal Antibodies for the Treatment of Respiratory Conditions
 - viii. Nasal Antihistamines/Nasal Anti-Inflammatory Steroids
 - ix. Oral Inhaled Glucocorticoids
 - x. Phosphodiesterase-4 Inhibitors
 - xi. Pulmonary Antihypertensives



b) Anti-Infectives

- i. Antivirals - Anti-Herpetic Agents
- ii. Antivirals - Influenza Agents
- iii. Cephalosporins - 3rd Generation
- iv. Fluoroquinolones
- v. Hepatitis C Agents
- vi. Macrolides
- vii. Ophthalmic Antibiotics
- viii. Ophthalmic Antibiotics/Corticosteroid Combinations
- ix. Oral Non-Systemic Antifungals
- x. Otic Antibiotics
- xi. Systemic Antifungals
- xii. Topical Antifungals
- xiii. Topical Antivirals
- xiv. Topical Antivirals and Anti-Inflammatory Steroid Combinations
- xv. Vaginal Antimicrobials

c) Cardiovascular

- i. Angiotensin-Converting Enzyme (ACE) Inhibitors
- ii. ACE Inhibitor Combinations
- iii. Alpha Adrenergic Blockers
- iv. Angiotensin II Receptor Antagonists (ARBs)
- v. ARB Combinations
- vi. Beta Adrenergic Blockers
- vii. Beta Adrenergic Blockers with Diuretics
- viii. Calcium Channel Blockers (CCBs)
- ix. CCBs with HMG-CoA Reductase Inhibitors
- x. Miscellaneous Cardiac Agents

d) Lipotropics

- i. Bile Acid Sequestrants
- ii. Fibrin Acid Derivatives
- iii. HMG-CoA Reductase Inhibitors

- iv. Lipotropics
 - e) Antimigraine Agents
 - f) Electrolyte Depleters
 - g) Multiple Sclerosis Agents
- 5. New Business
- 6. Public Comment
- 7. Other Business
- 8. Adjourn

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

https://teams.microsoft.com/l/meetup-join/19%3ameeting_Mjk5ZDhhNjMtNmM0Mi00Zjc3LWE1NTgtYWY5NTdjNWJhYTQ4%40thread.v2/0?context=%7b%22Tid%22%3a%22db05faca-c82a-4b9d-b9c5-0f64b6755421%22%2c%22Oid%22%3a%2253df74d0-e68c-46fe-81f5-fac4b0bd8ef8%22%7d

Join with a video conferencing device

425899727@t.plcm.vc

Video Conference ID: 115 290 275 6

[Alternate VTC instructions](#)

Or call in (audio only)

[+1 952-222-7450,645455664#](tel:+1952227450645455664) United States, Bloomington

Phone Conference ID: 645 455 664#